- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Low-Grade Albuminuria Linked With increased All-Cause mortality and CV Mortality
Albuminuria is known as a predictor of all-cause mortality and cardiovascular (CV) mortality. Thus, the importance of albuminuria has been emphasized and monitoring of albuminuria is recommended in high-risk patients, such as those with diabetes mellitus (DM) or chronic kidney disease (CKD).
In a recent study, researchers of Korea reported that low-grade albuminuria was associated with all-cause mortality and cardiovascular mortality. The study findings were published in the journal Kidney 360 on November 5, 2021.
Several previous studies showed that low-grade albuminuria was associated with all-cause mortality. However, these studies were limited to the high-risk patients such as patients with DKD and hypertension or, in the case of the old-aged participants. In addition, evidence from a large-scale population is lacking. Therefore, Jung Pyo Lee and his team conducted a study to further evaluate the association of low-grade albuminuria within the normal range with all-cause mortality and cardiovascular (CV) mortality.
It was an observational cohort study in which the researchers included 43,396 patients who participated in the National Health and Nutrition Examination Survey (1999-2016). They divided the patients into four quartiles of albumin-creatinine ratio (ACR). The major outcome assessed was all-cause mortality, and they also assessed the CV mortality. They used multivariable Cox proportional hazards models for statistical analysis.
Key Findings of the Study were:
- During a median of 7.9 years follow-up, the researchers observed 3,516 (9.1%) patients died.
- When compared with the reference group (Q1, ACR <4.171 mg/g), they found that low-grade albuminuria groups were associated with all-cause mortality (Q3, 6.211 ≤ ACR <10.010 mg/g, hazard ratio [HR] 1.25 ; Q4, ACR ≥10.010 mg/g, HR 1.57) in a multivariable hazards model.
- They also found a similar pattern in the association of low-grade albuminuria with CV mortality.
- Upon subgroup analyses, they noted that low-grade albuminuria was also associated with all-cause mortality in the nondiabetic group, non-hypertensive group, and non-chronic kidney disease group (estimated glomerular filtration rate ≥60 ml/min per 1.73 m^2).
The authors concluded, "Our findings suggest that low-grade albuminuria is associated with all-cause mortality and CV mortality. Low-grade albuminuria should be monitored even for patients with few cardiovascular risks." They further added, "In the general population, low-grade albuminuria should be carefully monitored."
For further information:
DOI: https://doi.org/10.34067/KID.0003912021
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751